Abstract:Yu-Bin Liu, 1, 2 Yun Liu, 1, 3 Lin Zhang, 1 Xing-Chen Zhou, 1 Bo-Yuan Ren, 1 Can Zheng, 1 Chun-Hua Hao, 4 Wei-Ting Wang, 4 Xia Xia, 5 Gang-Qiao Zhou, 1, 3 Chu-Tse Wu, 1 Ji-De Jin 1 1 Department of Experimental Hematology and Biochemistry, Beijing Institute of Radiation Medicine, Beijing, People's Republic of China; 2 Division of (Bio) Pharmaceutics, Institute of Zhejiang University - Quzhou, Zhejiang, People's Republic of China; 3 School of Medicine, Guizhou University, Guiyang, People's Republic of China; 4 Center for Pharmacodynamic Research, Tianjin Institute of Pharmaceutical Research, Tianjin, People's Republic of China; 5 Beijing SH Biotechnology Co., Ltd., Beijing, People's Republic of China Correspondence: Chu-Tse Wu; Ji-de Jin, Email ; Background: Whether anticoagulant therapy should be used after spinal-cord injury (SCI) surgery was controversial. The anticoagulation characteristics of a newly developed anticoagulant, recombinant neorudin (EPR-hirudin (EH)), were explored using a rat model of SCI to provide a basis for clinical anticoagulation therapy of SCI. Methods: A rat model of SCI was developed by Allen's method. Then, thrombosis in the inferior vena cava was induced by ligation. The low-bleeding characteristics of EH were explored by investigating dose–response and time–effect relationships, as well as multiple administration of EH, on thrombus formation complicated with SCI. Results: EH inhibited thrombosis in a dose-dependent manner by reducing the wet weight and dry weight of the thrombus. An inhibiting action of EH on thrombosis was most evident in the group given EH 2 h after SCI. After multiple intravenous doses of EH, thrombosis inhibition was improved to that observed with low molecular weight heparin (LMWH) (87% vs 90%). EH administration after SCI neither increased bleeding in the injured spine nor damaged to nerve function. Bleeding duration and activated partial thromboplastin time were increased in the high-dose EH group compared with that in the normal-saline group, but were lower than those in the LMWH group. Conclusion: EH can reduce thrombus formation in a rat model of SCI, and bleeding is decreased significantly compared with that using LMWH. EH may prevent thrombosis after SCI or spinal surgery. Keywords: recombinant neorudin, rat model, thrombosis, spinal-cord injury, low-bleeding anticoagulation Deep-vein thrombosis (DVT) is a common early complication after spinal-cord injury (SCI) and spinal surgery, but it can also occur in the chronic period. 1 DVT causes long-term swelling and ulcers in the lower limbs, and affects the rehabilitation and prognosis of patients. DVT can even lead to a fatal pulmonary embolism, 2 the third most common cause of death in patients with SCI, whose worldwide prevalence is estimated to be ≤5%. 3 In recent years, the prevalence of DVT after SCI has been increasing. 4–6 The overall prevalence of symptomatic or asymptomatic DVT in untreated SCI patients ranges from 50% to 100%, which is highest within the first 2 weeks following injury. 7–11 Full attention should be paid to the evaluation and prevention of DVT after SCI because efficacious treatment is lacking and the early clinical symptoms of DVT are not obvious. Whether anticoagulant therapy should be used in surgery for SCI was controversial, and different clinical opinions have been documented. Anticoagulant therapy may reduce the risk of DVT, but may increase the risk of epidural hematomas. 12 Application of anticoagulants before surgery, in general, can lead to bleeding, which interferes with anticoagulant therapy for patients with SCI. In particular, some scholars believe that intraoperative use of anticoagulants can lead to increased bleeding from wounds, formation of epidural hematomas, and other complications. 13 However, many scholars believe that patients with SCI should receive anticoagulants as soon as possible after SCI. Clinical studies have indicated that rational use of anticoagulants, such as low-molecular-weight heparin (LMWH), could reduce the occurrence of thrombosis without increasing the risk of bleeding. 3,14–19 Recombinant neorudin (EPR-hirudin (EH)) 20 is a newly developed anticoagulant. It is obtained by adding EPR short peptide (which is composed of three amino acids, Glu–Pro–Arg) to the N-terminal of hirudin (the most potent natural inhibitor of thrombin). Hirudin has been approved by the US Food and Drug Administration for the prevention of thrombosis after major orthopedic surgery. However, -Abstract Truncated-

Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Recombinant Neorudin, a New Anticoagulant Drug in Patients With Acute Coronary Syndrome

Recombinant neorudin and its active metabolite hirudin: the fate in vivo of a novel anticoagulant drug

Recombinant Neorudin for the Prevention of Deep-Vein Thrombosis After Spinal-Cord Injury

Effects of Intracoronary administration of nitroprusside on no-reflow phenomenon during emergency percutaneous coronary Intervention in patients with acute myocardial infarction

Pharmacokinetic study with N-Ile1-Thr2-63-desulfato-r-hirudin in rabbits by means of bioassay

[Comparison of the Antithrombotlic Effect and Safety Between Intravenous Nadroparin and Unfractionated Heparin in Patients Undergoing Percutaneous Coronary Intervention].

Safety, Tolerability, and Pharmacokinetics of Recombinant Human Neuregulin-1 in Healthy Chinese Subjects

Effectiveness and Safety of Nadroparin in Acute Coronary Syndrome

The antithrombotic effect of a novel hirudin derivative after reconstruction of carotid artery in rabbits

Bivalirudin Versus Unfractionated Heparin During Percutaneous Coronary Intervention in High-Bleeding-risk Patients with Acute Coronary Syndrome in Contemporary Practice

Efficacy and Safety of the Reduced Bivalirudin in Patients Undergoing Coronary Angiography or Percutaneous Coronary Intervention Stratified by Renal Function (REDUCE BOLUS): A Single-Blind, Stratified Randomized, Non-inferiority Trial

[The safety and efficacy of pre-treatment with enoxaparin (Clexane) in acute coronary syndrome patients undergoing percutaneous coronary intervention].

Effects of Recombinant Human Erythropoietin on Platelet Activation in Acute Myocardial Infarction: Results of a Double-Blind, Placebo-Controlled, Randomized Trial

Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study

Effect of Rivaroxaban vs Enoxaparin on Major Cardiac Adverse Events and Bleeding Risk in the Acute Phase of Acute Coronary Syndrome: The H-REPLACE Randomized Equivalence and Noninferiority Trial

Occurrence and Risk Factors of Adverse Drug Reactions in Patients Receiving Bivalirudin as Anticoagulant During Percutaneous Coronary Intervention: A Prospective, Multi-Center, Intensive Monitoring Study

Clinical Efficacy and Safety of Reduced-Dose Prasugrel After Percutaneous Coronary Intervention for Taiwanese Patients with Acute Coronary Syndromes

[A Large-Scale, Multicenter, Retrospective Study on Efficacy of Bivalirudin Use During Peri-Percutaneous Coronary Intervention Period for Chinese Patients with Coronary Heart Disease].

Efficiency and safety of bivalirudin in patients undergoing emergency percutaneous coronary intervention via radial access: A subgroup analysis from the bivalirudin in acute myocardial infarction versus heparin and GPI plus heparin trial

Efficacy and Safety of Recombinant Human Prourokinase in Acute Ischemic Stroke: A Phase IIa Randomized Clinical Trial

Effects of recombinant human erythropoietin on antiplatelet action of aspirin and clopidogrel in healthy subjects: results of a double-blind, placebo-controlled randomized trial.